Dose-Dense Primary Chemotherapy, as Part of Multidisciplinary Treatment, for Inoperable Stage III B Breast Cancer – Long-Term Results of a Phase II Trial

Publisher： Karger

E-ISSN： 1423-0232|72|1-2|17-26

ISSN： 0030-2414

Source： Oncology, Vol.72, Iss.1-2, 2007-11, pp. : 17-26

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Long-Term Follow-Up of a Phase II Trial of Six Cycles of Dose-Dense R-CHOP-14 for First-Line Treatment of Diffuse Large B-Cell Lymphoma in Young and Elderly Patients

By  

Acta Haematologica, Vol. 136, Iss. 2, 2016-05 ,pp. : 76-84

Karger

Access to resources Recommend Favorite

Long-Term Efficiency and Toxicity of Adjuvant Dose-Dense Sequential Adriamycin-Paclitaxel-Cyclophosphamide Chemotherapy in High-Risk Breast Cancer

By  

Oncology, Vol. 78, Iss. 3-4, 2010-06 ,pp. : 271-273

Karger

Access to resources Recommend Favorite

Dose-Dense Neoadjuvant Chemotherapy plus Radical Surgery in Locally Advanced Cervical Cancer: A Phase II Study

By  

Oncology, Vol. 89, Iss. 2, 2015-04 ,pp. : 103-110

Karger

Access to resources Recommend Favorite

Long‐term cardiac safety and outcomes of dose‐dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer

By  

CANCER, Vol. 119, Iss. 22, 2013-11 ,pp. : 3943-3951

John Wiley & Sons Inc

Access to resources Recommend Favorite

Five-Year Update of an Expanded Phase II Study of Dose-Dense and -Intense Doxorubicin, Paclitaxel and Cyclophosphamide (ATC) in High-Risk Breast Cancer

By  

Oncology, Vol. 69, Iss. 5, 2005-12 ,pp. : 372-383

Karger

Access to resources Recommend Favorite